Deutsche Bank Initiates Coverage on Acumen Pharmaceuticals https://www.nasdaq.com/articles/deutsche-bank-initiates-coverage-of-acumen-pharmaceuticals-abos-with-buy-recommendation
Their $8 price target would but Acumen at a market cap of almost $500M.
They have $282M in cash on hand. https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-third-quarter-2023-financial
Their cash on hand will be used for Phase 2/3, so adjusted market cap would be closer to $220M.
PMN's current market cap is $18M.
PMN has room to run. Assuming PMN follows the same trajectory as ABOS, the market cap could go to $500M upon completing two milestones. The first would be financing for Phase 2. The second would be successful completion of Phase 1. The Phase 2 financing would be highly dilutive at the current stock price... likely 200 million new shares to raise $200M. So my percent ownership of the company would decrease by a factor of 10 or so, and total number of shares would probably be around 220 million. At a market cap of $500M, the price per share would be around $2.27.
What the shareholders desparately need is for PMN to market their product more so that the current PPS goes up and so that they finance at a much higher PPS. The financing would be less dilutive and the ROI would go up to levels commensurate with the investment risk.
Will PMN actually market their product? Clearly they had some success in generating interest after AAIC 2023... so why can't they take that message to the masses?